Abstract 443P
Background
The low survival rate of cancer patients, especially patients who got metastases, necessitates an approach in providing additional therapy that is safe, capable of delaying disease progression, and prolonging patient survival. Vitamin D is an adjunctive therapy that is easy to obtain and shows anti-neoplastic activity against cancer so that it can reduce mortality. This study aimed to conduct a systematic review and meta-analysis regarding the efficacy of vitamin D supplementation in overall survival (OS) of cancer patients.
Methods
A systematic search of various databases up to end of 2022 was conducted to identify Randomized Controlled Trials (RCTs) involving the efficacy of vitamin D supplementation in OS of cancer patients. By using a random effect model, pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated to determine the values of OS. In formulating the study problem, we determine the study questions based on the study background, which consists of the populations (P), interventions (I), comparisons (C), and outcomes (O). The populations were cancer patients. The intervention was administration of vitamin D supplementation. The comparison was no administration of vitamin D supplementation. The outcome was OS. The RCTs having cancer patients over 18 years of age with available and sufficient information about OS were the inclusion criteria of this study. Study that has participants taking vitamin D supplementation regularly, and ongoing study with results not presented or published at the time of the literature search were the exclusion criteria of this study.
Results
Of the six RCTs, analysis was performed on 1,916 cancer patients in this study. In terms of survival, statistically, there was no difference in OS [HR 0.97, 95% CI 0.74 – 1.28, p = 0.85] between vitamin D supplementation and no supplementation in cancer patients.
Conclusions
Although vitamin D supplementation does not improve OS in cancer patients, is could be considered because it still shows benefits for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract